Author:
Fukae Jiro,Hattori Nobutaka
Publisher
Springer International Publishing
Reference24 articles.
1. Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Antonini A. Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson’s disease: efficacy, safety and patient selection. Funct Neurol. 2012;27(3):147–54.
2. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–58.
3. Amjad F, Bhatti D, Davis TL, Oguh O, Pahwa R, Kukreja P, Zamudio J, Metman LV. Current practices for outpatient initiation of levodopa-carbidopa intestinal gel for Management of Advanced Parkinson’s disease in the United States. Adv Ther. 2019;36(9):2233–46.
4. Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, Onuk K, Odin PLA. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34(12):2063–73.
5. Bredberg E, Nilsson D, Johansson K, Aquilonius SM, Johnels B, Nyström C, Paalzow L. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson’s disease. Eur J Clin Pharmacol. 1993;45(2):117–22.